Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non–Small Cell Lung Cancer
Shan Li, PharmD, BCOP, and Eve M. Segal, PharmD, BCOP
University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Shan Li, PharmD, BCOP, Clinical Oncology Pharmacist, University of Washington Medical Center/Seattle Cancer Care Alliance, 825 Eastlake Avenue East, MS G5-900, Seattle, WA 98109. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2017;8:196–201 |
© 2017 Harborside Press®
For access to the full length article, please sign in